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LThe trachea: The first tissue-engineered organ?Pierre R. Delaere, MD, PhD,a and Dirk Van Raemdonck, MD, PhDbMajor medical breakthroughs deserve the necessary
press attention to inform the medical community and
public of the news. Unfortunately, misrepresentation of
medical information can occur and is particularly problem-
atic when members of the professional and public press
are misled to believe unrealistic medical breakthroughs.
In 2008 and 2011, 2 revolutionary articles were published
in The Lancet reporting on regeneration of a tracheal
transplant.1,2 The tracheal transplant procedure used stem
cells extracted from the patient’s bone marrow in
conjunction with a synthetic scaffold to create the
artificial organ. In September 2012, an article printed in
The New York Times, ‘‘A First: Organs Tailor-Made With
Body’s Own Cells,’’3 recognized tracheal regeneration as
the first regenerative medicine procedure designed to
implant ‘‘bioartificial’’ organs. This achievement was
touted as the beginning of complex organ engineering for
the heart, liver, and kidneys, and it was suggested that
allotransplantation along with immunosuppression might
become problems of the past.3
Two questions, however, remain: (1) How does a
synthetic tube transform into a viable airway tube? (2) Is
the trachea really the first bioengineered organ?REGENERATION VERSUS SECONDARY WOUND
HEALING
In reports on bioengineered tracheas, it is frequently
stated that the trachea is well suited to tissue engineering
because it consists of a hollow, relatively simple structure.
In reality, however, the trachea has an ingenious
morphology that allows it to fulfill its function (Figure 1,
A). It is thus one of the most difficult organs of the human
body to replace.4 To date, regeneration within the airway
tract is only possible for epithelial defects above the
basement membrane. If a tissue injury is severe and
involves damage to both epithelial cells and the submucosal
layer, healing will be accomplished by secondary intention,
leading to stenosis of the airway (Figure 1, B). The current
challenge for regenerative medicine is to overcomeFrom the Departments of Otolaryngology Head & Neck Surgerya and Thoracic Sur-
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full-thickness mucosal defects, which is not yet possible
(Figure 1, C).PROSTHETIC VERSUS REGENERATED TRACHEA
Tracheal regeneration for airway repair with bio-
engineered constructs typically consists of a cartilaginous
tube lined with viable respiratory mucosa.1,2 These
constructs are created with bone marrow stem cells and
growth factors (of which the clinical value for tissue
healing is unknown) that are applied to a nonvascularized
scaffold. The mechanism behind the transformation from
nonviable construct to viable airway cannot be explained
with our current knowledge of tissue healing, tissue
transplantation, and tissue regeneration. In fact, cells have
never been observed to adhere, grow, and regenerate into
complex tissues when applied to an avascular or synthetic
scaffold. Moreover, this advanced form of tissue
regeneration has never been observed in laboratory-based
research.
Of the 14 patients who have received bioengineered
tracheas,5 3 have been described in case reports in 4
different articles (the first patient was described after both
6-month and 5-year follow-ups).1,2,6,7 In these articles, 2
different scaffolds (2 cases with an enzymatically
decellularized tracheal allotransplant1,6,7 and 1 case with a
synthetic nanocomposite2) were reported as being used,
along with 2 different techniques of applying bone marrow
cells to the scaffold (2 cases with a bioreactor for ‘‘ex vivo’’
use1,2,7 and 1 case where the bone marrow cells were
applied ‘‘in vivo’’6). Production of the bioengineered
trachea in all cases produced similar results, and the
different approaches worked in comparable ways. Informa-
tion gathered from published reports on these 3 patients and
unpublished reports on an additional 11 patients suggests
that mortality and morbidity were very high.5 More than
half of the patients died within a 3-month period, and the
patients who survived longer functioned with an airway
stent that preserved the airway lumen.
From this information, it can be concluded that the
bioengineered tracheal replacements were in fact airway
replacements that functioned only as scaffolds, behaving
in a similar way to synthetic tracheal prostheses. In
recent years, most synthetic materials used for tracheal
replacement have been tested in experimental animal
research. From these studies, it became clear that
definitive prosthetic replacement of the airway wall is not
possible.8 To date, nearly all surgical prostheses that
have been successful were observed in potentially sterilegery c April 2014
FIGURE 1. Wound healing of a tracheal mucosal defect. A, The trachea has a segmental blood supply that reaches the mucosal lining through the intercartila-
ginous ligaments and themembranous trachea (A1 andA2). The basementmembrane of themucosal layer supports a pseudostratifiedepithelium, the surface layer
of which is columnar and ciliated, with deeper layers of basal cells. A superficial epithelialwound can heal through regeneration of the surface epithelium (A3). B,
Thehealingpatternof a circumferential full-thicknessmucosaldefect (B1andB2) is shown.Healingof full-thicknessmucosalwounds combines granulation tissue
formation,wound contraction, and reepithelialization from thewound edges (arrows).Airway stenosis in themiddle part of the denuded segment candevelop from
circumferential wounds. Healing of anastomotic sites can enable several millimeters of respiratory epithelium to grow into the wound margins (B3) while the
remaining tissue between thosemargins is left as uncovered granular tissue (B4 andB5). C, Research in tracheal tissue engineering should concentrate on attempts
to regenerate the mucosal lining by applying epithelial stem cells (C1 and C2) to a tracheal segment with a preserved blood supply and cartilaginous support.
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FIGURE 2. Prosthetic versus regenerated trachea A, Blood vessel prosthesis. Endothelialization of the luminal surface of vascular grafts occurs only 1 to 2
cm into the graft from the anastomotic site. These endothelial cells are derived from adjacent, native arterial endothelium, and they enable the anastomosis to
heal. B, In the respiratory tract, the flow of inspired air will lead to bacterial contamination and wound breakdown at the anastomoses. The respiratory
epithelium will not grow over the prosthesis-airway anastomosis. C, Airway prosthesis wrapped in vascularized tissue. A prosthesis may act as a temporary
airway stent when it is wrapped by well-vascularized tissue (eg, omentum). The vascularized tissue around the prosthesis can temporary avoid the
complications of wound breakdown at the anastomotic sites. D, A scaffold soaked in bone marrow cells will behave in similarly to a prosthesis. Granulation
tissue at the anastomoses will be formed in patients surviving for longer periods. E, A stent can be placed as a temporary airway.
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repair can be cited in the respiratory, gastrointestinal, or
genitourinary tract. The internal site of the airway tract1130 The Journal of Thoracic and Cardiovascular Surbelongs to the outside world, and bacterial contamination
at the interface between the airway and prosthesis
prevent its ingrowth (Figure 2). The complications ofgery c April 2014
FIGURE 3. Visualization of the bioengineered tissue approach when applied to an external ear (theoretic example). A, The external ear has a comparable
tissue composition (cartilage framework and epithelial lining) to the trachea. Here, an enzymatically decellularized allograft treated with bone marrow cells
and cultured epithelial cells is attached to a recipient area without restoration of the blood supply. B, Direct visualization of the healing and revascularization
of the bioengineered ear should be mandatory to prove (the hypothetical) success of the bioengineering process.
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delayed by wrapping the prosthesis in vascularized
tissue, mostly transposed omentum. This is exactly what
occurred in nearly all cases of the supposedly bioengineered
tracheal replacements. The scaffolds were wrapped in
vascularized omentum so that inevitable complications
could be delayed. In patients who survive for longer
periods, granulation tissue will form at the suture lines,
a complication that necessitates placement of a stent to
preserve the airway lumen temporarily (Figure 2, E).VISUALIZATION OF BIOENGINEERED TISSUE
It seems contradictory that one of the most difficult
organs to replace has been reported as being the first
bioengineered organ. How can a synthetic tracheal
replacement, destined to fail, be described as a major
breakthrough in organ tissue engineering?
The dissemination of misleading information regarding
bioengineering of complex tissues would not be possible
in tissues that can be directly visualized (Figure 3). For a
tracheal replacement, direct visualization of the transplant
and subsequent healing is only possible in an experimental
setting and during autopsy. Neither of these methods,
however, were used to document the tissue-engineered
tracheas in the 14 previous patients. Tracheal bio-
engineering was not tested in animal models, and despite
the fact that several patients died after having received
the bioengineered tracheal replacement, no postmortem
histologic data have been published. Although in vivo
visualization of tracheal transplants and their healing
process is possible with serial computed tomographic
scanning and endoscopic imaging performed at regular
intervals after implantation, clear visualization of the trans-
plant is lacking in all reports regarding the bioengineeredThe Journal of Thoracic and Cartrachea. Published computed tomographic images and
endoscopic views show only images produced shortly after
transplantation and either do not allow the clear visualiza-
tion of the transplant or were obtained with an airway stent
in place.1,2,6,7 In an editorial in Science discussing the
controversy of this topic,5 the main scientist behind the
bioengineering approach acknowledged that ‘‘it was
difficult to tell what exactly had happened inside the
implanted tracheas,’’ which is remarkablewhen considering
the high-quality computed tomographic scans and endo-
scopic approaches that are currently available.
The media hype regarding ‘‘stem cells’’ and the work
done on an airway that is less accessible for direct
visualization are key elements that explain publication of
these papers in highly ranked medical journals.1,2,6,7,9
In conclusion, the ethical justification of tracheal replace-
ment with a synthetic prosthesis or with a decellularized
allograft in humans is questionable, because there are no
available experimental data describing a possible successful
outcome. The currently available published articles on
bioengineered tracheas and the resulting media attention
endanger the field of tracheal replacement and the field of
tissue engineering as a whole. For patient safety, tracheal
bioengineering must be demonstrated as being efficacious
and safe before further transplants.References
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